In response to the tragic deaths of at least 23 children in Madhya Pradesh linked to toxic cough syrups, the Central Drugs Standard Control Organisation (CDSCO) has rolled out a digital monitoring system to track the supply chain and quality of high-risk pharmaceutical solvents. The initiative seeks to prevent future contamination incidents caused by substances like Diethylene Glycol (DEG), which has repeatedly caused fatal poisonings.
Global Pressure and Domestic Action
The move follows increasing international scrutiny of India’s drug manufacturing standards. The World Health Organization (WHO) has previously flagged lapses connected to DEG-contaminated medicines that raised global health alarms. To strengthen domestic regulatory control, the Drugs Controller General of India (DCGI), Dr. Rajeev Singh Raghuvanshi, issued a circular directing all State and Union Territory drug controllers to ensure that manufacturers of pharma-grade solvents acquire manufacturing licences through the Online National Drugs Licensing System (ONDLS) portal.
Enhanced Digital Tracking Mechanism
According to the circular, the ONDLS portal has been upgraded with a new digital monitoring system that enables real-time tracking of the supply chain and quality of solvents such as DEG. The system will help manufacturers and vendors improve traceability and accountability. High-risk solvents under this monitoring framework include glycerin, propylene glycol, maltitol, sorbitol, hydrogenated starch hydrolysate, polyethylene glycol (MW <1000), polysorbates, and ethyl alcohol.
Mandatory Batch-Wise Uploads
Under the revised protocol, pharmaceutical solvents manufacturers are now required to upload detailed batch-wise information — including quantities produced, Certificates of Analysis (CoA), and vendor details — onto the ONDLS portal. Authorities instruct state regulators to verify manufacturers’ records. They must ensure no batch of these solvents is released into the market without complete documentation.
Industry and Regulatory Perspectives
Sumant K. Tiwari, Joint Director of the Drugs Control Department in Jharkhand, emphasized that the ONDLS integration could serve as a national model for transparent oversight. “If the digital system proves effective, it may evolve into a centralized quality grid for drug licensing, inspection, and raw material traceability on one platform,” he said. However, he also cautioned that the initiative remains narrow in focus. “This patchwork reform targets only one component of the production chain,” Tiwari noted, urging a comprehensive overhaul of India’s regulatory architecture.
Aftermath of the Coldrif Tragedy
Earlier this month, 23 children in Chhindwara, Madhya Pradesh, died after consuming Coldrif cough syrup that contained DEG. The toxic batch was traced to Sresan Pharmaceuticals, a Chennai-based firm. Following the incident, authorities shut down the company’s manufacturing unit, revoked its licence, and arrested its proprietor, G. Ranganathan, with support from Tamil Nadu police.
A Step Towards Safer Medicines
The Hindu Business Line reports that the CDSCO’s digital initiative is a crucial step in restoring confidence in India’s pharmaceutical quality control. It aims to enhance transparency and traceability in the drug supply chain.It enhances transparency and traceability. However, experts believe that only a unified, nationwide digital framework can be effective. They say it is essential to prevent such fatal lapses in the country’s drug supply chain.